Fed. Circ. Sides With Sanofi In Patent Spat With Novo

Law360, New York (July 30, 2008, 12:00 AM EDT) -- A federal appeals court has affirmed a district court's denial of Novo Nordisk A/S's request for a preliminary injunction in the drugmaker's yearlong patent feud with Sanofi-Aventis over a top-selling insulin injection device.

In the U.S. Court of Appeals for the Federal Circuit on Wednesday, circuit judges affirmed the U.S. District Court for the District of New Jersey's February ruling that Novo lacked a “reasonable likelihood” of winning the case.

The patent spat is over Sanofi's SoloStar product, a once-a-day insulin injection pen that Novo claims...
To view the full article, register now.